Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEN003694 + Talazoparib in Triple-Negative Breast Cancer
NCT03901469Phase 2Terminated
- Sponsor
- Zenith Epigenetics
- Start
- Jun 2019
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of ZEN3694 in triple-negative breast cancer (TNBC), sponsored by Zenith Epigenetics. Started Jun 2019; status: terminated.
02
Drugs
ZEN3694
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03901469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03901469.